Sight Sciences, Inc. (SGHT) Financial Analysis & Valuation | Quarter Chart
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduc... more
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercia... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $483.70M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Paul Badawi |
| IPO Date | 2021-07-15 | CAGR | 39.49% |
| Employees | 186 | Website | www.sightsciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SGHT chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $355.58M | P/E | -15.87 | Forward P/E | -20.57 | PEG | — |
| P/S | 9109.35 | P/B | 14381.85 | P/CF | -25157.28 | P/FCF | -24969.9 |
| Sales | $83.38M | Sales 1Y | 9.27% | Sales 3Y | 2.28% | Sales 5Y | 114.82% |
| EPS | $-0.56 | EPS 1Y | -41.83% | EPS 3Y | -61.75% | EPS 5Y | -53.47% |
| Sales QoQ | 18.73% | EPS QoQ | -66.67% | Sales QoQ Avg | 4.88% | EPS QoQ Avg | 14.51% |
| Gross Margin | 87.96% | Operating Margin | -33.43% | Profit Margin | -35.69% | ROCE | -33.04% |
| ROA | -28% | ROE | -51% | Altman Z Score | 1.12 | Piotroski Score | 3 |
| Current Ratio | 4.95 | Quick Ratio | 4.67 | Cash Ratio | 3.89 | Op. CF Ratio | -0.62 |
| Debt/Equity | 0.79 | Debt/Assets | 0.4 | Lt Debt/Equity | 0.59 | Lt Debt/Cap. | 0.37 |
| Intrst Cov. | -10.65 | Inventory Turnover | 1.76 | Asset Turnover | 0.8 | Receivables Turnover | 7.32 |
| Enterprise Value | $355.58M | P/E Ratio | -15.87 |
| Forward P/E | -20.57 | PEG Ratio | — |
| P/S Ratio | 9109.35 | P/B Ratio | 14381.85 |
| P/CF Ratio | -25157.28 | P/FCF Ratio | -24969.9 |
| EPS | $-0.56 | EPS Growth 1Y | -41.83% |
| EPS Growth 3Y | -61.75% | EPS Growth 5Y | -53.47% |
| Revenue Growth 1Y | 9.27% | Gross Margin | 87.96% |
| Operating Margin | -33.43% | Profit Margin | -35.69% |
| ROE | -51% | ROA | -28% |
| ROCE | -33.04% | Current Ratio | 4.95 |
| Quick Ratio | 4.67 | Cash Ratio | 3.89 |
| Debt/Equity | 0.79 | Interest Coverage | -10.65 |
| Altman Z Score | 1.12 | Piotroski Score | 3 |
Sight Sciences, Inc. (SGHT) valuation & financials
Sight Sciences, Inc. (SGHT) has a market capitalization of $483.70M and trades at a price-to-earnings ratio of -15.9. It operates in the Healthcare sector (Medical - Devices).
Sight Sciences, Inc.'s revenue grew +9.3% over the last year.
Sight Sciences, Inc.'s next earnings report is scheduled for November 5, 2026 (provider scheduled date); analysts estimate EPS of $-0.13. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)